Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• The bone marrow microenvironment (BME) is vital for hematopoiesis but is frequently altered in hematologic cancers.
• Tumor-associated macrophages (TAMs) are key players in the tumor microenvironment (TME), driving tumor progression.
• Modulating TAMs presents a significant therapeutic opportunity in cancer treatment.

Purpose of the Study:

• To review the role of the TME in hematologic malignancies.
• To identify and discuss potential targets for modulating immunosuppressive TAMs.
• To explore innovative therapeutic strategies for combating the immunosuppressive TME.

Main Methods:

• Literature review of the TME and TAMs in hematologic malignancies.
• Identification of various molecular targets on TAMs.
• Discussion of novel therapeutic approaches, including CAR T/NK-cell therapies.

Main Results:

• The TME significantly influences hematologic malignancies.
• Numerous targets (e.g., CD123, CSF1R, CD47, CD206) exist for TAM modulation.
• Combination therapies, including cell-based approaches, show promise.

Conclusions:

• Targeting TAMs is a critical strategy for overcoming the immunosuppressive TME in hematologic cancers.
• Innovative approaches combining cell therapies with other treatments can enhance patient survival and quality of life.
• Further research into TAM modulation is essential for advancing cancer therapy.